Exhibit 99.1 Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional$7.00 per share in cash through a contingent value right ("CVR") upon the achievement of a regulatory milestone, for a total equity value of up to approximately $1.7 billion; Expected to be completed in the second half of 2025, subject to customary closing conditions Positive topline data fr ...